Gene therapy

Neuroscience
#Drug discovery #Gene therapy #Neurology #Neuroscience #Webinar

DDW Neuroscience webinar: Opportunities for drug discovery

Hosted by Drug Discovery World and supported by BioIVT, this webinar examines the advances, challenges and opportunities that exist in neuroscience drug discovery and development. You will hear from a number of experts who will discuss how both technology and scientific approaches are helping enable the development of new therapies… Read More

Webinar date:
Sponsored by BioIVT
#Webinars

Blood cells
#FDA #Gene therapy #Paediatrics #Sickle cell disorder (SCD)

FDA expands use of Casgevy to children as young as two

The US Food and Drug Administration (FDA) has expanded the use of Casgevy (exagamglogene autotemcel) for the treatment of people ages two years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT).   The approval makes Casgevy the first approved genetic therapy… Read More

#News #Regulatory

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Gene therapy #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford #University of Queensland

This week in Drug Discovery (29 June – 3 July) 

News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW.  This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer.  The… Read More

#News

MRI of the brain
#epilepsy #Gene therapy #Protein

New gene therapy could prevent epilepsy, study suggests 

A new type of gene therapy that only activates when the brain is under stress could stop epilepsy before it fully develops, researchers say.  In a study led by Professor Tawfeeq Shekh-Ahmed of the School of Pharmacy at the Hebrew University of Jerusalem (HU), published in Signal… Read More

#News

#Base editing #Beam Therapeutics #FDA #Gene editing #Gene therapy #Rare disease

FDA clears base editing therapy for phenylketonuria

The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for Beam Therapeutics’ BEAM-304 for the treatment of phenylketonuria (PKU).   PKU is a rare, inherited metabolic disorder that results in toxic accumulation of phenylalanine (Phe), leading to serious neurologic and neurocognitive impairments and requires strict,… Read More

#News #Regulatory #Trending News

World Parkinson's Day
#AskBio #Blood brain barrier #FDA #Gene therapy #Parkinson's #Regulatory

How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease

Bruno Quinney speaks to Adrian Kells, Senior Vice President and Integrated Product Team Lead PD at AskBio, about the company’s gene therapy programme and pioneering treatment for Parkinson’s. The drug discovery landscape for Parkinson’s disease is becoming one of the most exciting frontiers in the industry. It is unsurprising to… Read More

#Exclusive Content

Sickle cells
#Gene therapy #Paediatrics #Sickle cell disorder (SCD) #Vertex

Vertex presents new data on Casgevy in children

Vertex Pharmaceuticals has announced data demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in people ages five years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).   The results, from pivotal studies in children ages 5–11, show that the efficacy and safety… Read More

#News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

DDW Highlights: 2 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More

#Podcasts

Heart
#AAV #Circio Holding #Gene therapy #Heart disease

Circio and AaviGen collaborate on heart disease gene therapy 

Biotechnology companies Circio Holding and AaviGen have announced a research collaboration to develop heart disease gene therapies.  The agreement will see the companies work to develop circVec-enhanced AAV vectors specifically engineered for targeted, low dose heart gene therapy.   The collaboration focus will be on addressing genetic… Read More

#News

Human brain
#Cancer research #Gene therapy #Trogenix

First patient dosed in glioblastoma gene therapy trial 

The first patient has been dosed in the Phase I/II clinical trial of a gene therapy for glioblastoma (GBM).  TGX-007, developed by oncology company Trogenix, is a dual-payload adeno-associated virus (AAV)-based gene therapy.   TGX-007 harnesses Trogenix’s proprietary Synthetic Super-Enhancer (SSE) technology to exploit the core cancer cell identity. The… Read More

#Cancer Research #News

#Alzheimer's #Brain cancer #Cardiovascular disease #Cholesterol #Colorectal cancer #Dementia #Ebola virus #Eli Lilly #Gene therapy #Genetic profiling #Immunology / Virology & Vaccines #Peptides #Stem cells #University of Reading #Vaccines

This week in Drug Discovery (25–29 May) 

News round-up for 25–29 May by Bruno Quinney, Content Team at DDW.  This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments.  The top stories:    UK group steps… Read More

#News

Cholesterol test
#Cardiovascular disease #Cholesterol #Eli Lilly #Gene therapy

Single-shot gene therapy could cut cholesterol by 62% 

A single-shot gene therapy could slash cholesterol levels by 62%, potentially ‘transforming cardiovascular care’.  Results from the Heart-2 study into VERVE-102, published in The New England Journal of Medicine, showed reductions of up to 62% in a cohort of 35 participants, with durability observed for up… Read More

#News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (18 – 22 May)

News round-up for 18 – 22 May by Bruno Quinney, Content Team at DDW.    This week, a report showed patients in Europe face barriers to patient access. Elsewhere, Wellcome prizes are facilitating research in both tropical disease and mental health.    The… Read More

#News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

DDW Highlights: 19 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research uncovered new treatment pathways for hard to treat breast cancers. Elsewhere,… Read More

#Podcasts

Cell therapy platform
#FDA #Gene therapy #Manufacturing

Cytiva’s transcient cell line receives FDA AMT designation 

The US Food and Drug Administration (FDA) has given an advanced manufacturing technology (AMT) designation to Cytiva’s transient cell line, making it one of the first gene therapy manufacturing technologies to receive the designation.   The ELEVECTA transient cell line for adeno-associated virus (AAV) manufacturing is said to reduce the formation and encapsidation of host cell DNA… Read More

#News #Regulatory

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (11 – 15 May) 

News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW.  This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis.  The top stories:   … Read More

#News